Despite advances in the treatment of lupus nephritis (LN), 10-15% of the patients proceed to end-stage renal failure. 1 Additionally, the standard treatment options pose a significant threat in terms of side effects to the patient, and even medication-related deaths occur, as documented in recent studies comparing MMF and cyclophosphamide. 2 New means of diagnosing and monitoring LN could help to improve the outcome of LN.
Systemic markers for SLE activity
Traditionally, serum levels of anti-dsDNA antibodies and hypocomplementemia are used to identify patients with high disease activity and at risk for developing LN. Although C3, C4 and anti-DNA antibodies are routinely used in clinical practice, several studies have shown that the sensitivity to detect renal flares is only between 50 and 70% and the specificity of all tests was below 75%. 3, 4 This implies that using these markers alone is insufficient to monitor LN. Determining additional autoantibodies in parallel may further increase the diagnostic impact. For example, anti-C1q antibodies have received increasing interest and several studies report negative predictive values for anti-C1q antibodies and LN between 97 and 100%. Therefore, in clinical practice, the lack of anti-C1q antibodies makes LN less likely in a given SLE patient. However, the positive predictive value of 27-68% in the presence of anti-C1q antibodies for LN is to low to reliably identify patients with LN (reviewed in 5 ).
Several new biomarkers for SLE have been published, which claim to mirror SLE activity and many are linked to a pathogenetic model. Systemic B cell activation and IFNα production are firmly accepted concepts in the pathogenesis of SLE, and several groups have reported biomarkers that reflect these pathogenetic features. An increase in the number of circulating plasmablasts/plasmacells and a decrease in naive B cells mirrors the systemic activation of B cells and identifies patients with active SLE with a sensitivity of 62,5% and a specificity of 88,9%. 6 Similarly, Siglec-1 expression on circulating monocytes, a surrogate marker for IFNα stimulation, correlates well with lupus activity. 7 In addition to these potentially interesting biomarkers, there is a whole plethora of surface markers, cytokines, chemokines, and cell subsets reported to correlate with SLE disease activity. Some of these markers reflecting activation of the SLE autoimmune response have great potential to assess the systemic disease activity. However, it is likely that these markers will have some limitations in the selective identification of patients with nephritis and in the monitoring of LN.
Urinary markers for LN
Biomarkers reflecting SLE disease activity and providing specificity for renal lupus manifestation are likely to be found in the urine. Proteinuria and urinary sediment are powerful tools to screen LN, but both have their limitations. Proteinuria can remain stable once it is established and therefore does not necessarily reflect active inflammation in the kidneys. This makes it difficult to predict which patient may need more treatment and which patients would not profit from intensified therapy. Additionally, proteinuria is best determined in the 24 h urine, which is time consuming and collection errors are a chronic problem. Urine sediment is readily obtained and identifies patient with active nephritis. However, urinary sediment gives only a semi quantitative result and is observer dependent, hampering its ability to monitor LN in follow up. Furthermore, residual remaining inflammation in the kidneys may easily be missed by the sediment. Therefore, proteinuria and sediment are good, but other urinary biomarkers could probably reflect LN better.
Cytokines, chemokines and interstitial infiltration
In our recent studies we envision that LN can be monitored best and maybe even diagnosed using urinary markers reflecting local kidney inflammation. As in any other inflammation, a diverse group of cytokines and chemokines is up regulated in the glomeruli and interstitium in SLE nephritis. This routinely leads to a recruitment of infiltrating cells into the kidney interstitium, which can be found in approximately 70% of all LN biopsies, especially in class IV nephritis. 8, 9 The 'true' occurrence of interstitial infiltration in LN might be even higher, since the infiltrate is often distributed in a patchy fashion. This is supported by studies in the NZB/W F1 mouse model for SLE, which develops a nephritis closely resembling class IV human LN, in which the infiltrating T and B cells are often found in circumscribed areas. If this holds true for human lupus nephritis as well, it may explain why an interstial infiltration is not always observed in human LN. Murine SLE models also offer insights into the kinetic of events leading to LN: up regulation of chemokines is one of the initial events in LN, followed by infiltration of mononuclear cells and overt nephritis with proteinuria and kidney damage. 10 If one extrapolates these findings to humans, monitoring kidney chemokine expression and inflammatory infiltration will yield valuable information about the activity of the kidney inflammation, potentially even prior to clinical manifest nephritis.
In recent years, several groups have reported that chemokines and cytokines can be measured in the urine, either by detecting their protein level using ELISA or their mRNA level in the sediment using RT-PCR ( 11-15 , see Table 1 ). The urinary levels of two different groups of chemokines/cytokines seem to correlate best with active LN, probably reflecting the importance of these [16] [17] [18] [19] pathways in the pathogenesis. One is the chemokine CCL2 (MCP-1), which is presumably responsible for the recruitment of monocytes/macrophages into the inflamed kidneys. Several studies have found an increase in urinary CCL2 in active LN. 20, 21 Additional support for the involvement of this chemokine comes from CCL2 knockout lupus prone MRL.lpr mice, which show an attenuated course of disease. 22 The other group of chemokines/ cytokines consists of CXCL10, CXCR3 and IFNγ, all elevated in the urine of patients with active LN and all indicative of the recruitment of Th1 T cells into the kidneys. 11, 16 Additionally, urinary mRNA levels of CXCR3, CXCL10, VGEF and TGFbeta seem to distinguish class IV LN from other types of SLE nephritis. 11 The urinary levels of the chemokine TWEAK also correlate well with SLE nephritis, and interestingly, this chemokine is thought to induce CCL2 and CXCL10 expression by renal cells. 15 In a complementary approach, our group has established that the infiltrating cells can be monitored in the urine from patients with active LN. From histology studies it is known that the leukocyte infiltration correlates with kidney damage and worse prognosis and that the majority of infiltrating cells are T cells. We analyzed urine samples from SLE patients with active nephritis by flow cytometry and observed abundant T cells in the urine. In contrary, patients with active disease without renal involvement presented hardly any urinary T cells. Similarly, in the urine of patients with known renal involvement but quiescent nephritis, T cells were almost absent from the urine. Urinary T cell counts of more than 2000 CD3 T cells per 100 mL urine identified patients with active nephritis, and the delineation between active and non-active nephritis was even better if only urinary CD3 + CD4 + T cells were analyzed. Elevated numbers of urinary T cells were also detect- Editorial P Enghard and G Riemekasten able in patients with LN in which a parallel performed biopsy was devoid of infiltrating cells. This may indicate that the cellular infiltration in LN is indeed patchy and might be missed by biopsy, while these cells can be detected in the urine. Furthermore, analysis of urinary T cells by flow cytometry offers the ability to further characterize the detected T cells, which certainly will increase the ability of this method to detect active LN. To investigate how these T cells are recruited into the inflamed kidney tissue, we determined the expression of CXCR3 on these cells. CXCR3 is a Th1 associated chemokine receptor and both CXCR3 expression and the corresponding chemokine CXCL10 can be detected abundantly in the cellular infiltration in LN biopsies. In patients with renal SLE involvement, the percentage of CXCR3 expressing urinary CD4 + T cells reflected disease activity as assessed by SLEDAI. Moreover, a selective enrichment of CXCR3 expressing CD4 + T cells in patients with active LN was found by comparing the T cells in the peripheral blood to the T cells in the urine. This enrichment of CXCR3 expressing T cells in the urine may indicate that the T cells are indeed recruited via CXCR3 from the blood into the kidneys. 23 These observations are in line with studies showing a correlation between the levels of urinary CXCL10 and CXCR3 expression and disease activity. 11 Some of the aforementioned markers have also been analyzed in the follow-up of patients treated for LN. The levels of urinary CXCL10, CCL2, CD4 + T cells have been reported to correlate with the clinical response in patients treated for LN, with responders showing a decline in the level of the respective marker. Interestingly, despite response to therapy, some patients showed a persistence of elevated levels of urinary CCL2 and CD4 + T cells despite clinical response to therapy. To date, it is uncertain whether this reflects ongoing subclinical inflammation or a risk for imminent relapse.
It is not known whether a urinary biomarker or a given combination of markers will be specific for LN and able to distinguish alternative renal pathologies. Interstitial infiltration of leukocytes can be found in a wide variety of renal diseases including diverse forms of glomerulonephritis, diabetic nephropathy and hypertonic kidney damage. It is likely that other chemokines and cytokines involved are also expressed in a broad range of kidney pathologies as well. 24 Therefore, elevation of urinary chemokines, cytokines or cells might not be absolutely specific for SLE nephritis. Nevertheless, urinary CD4 + T cells and other biomarkers could be a valuable additional tool to diagnose LN and will certainly help us to suspect LN, diagnose it earlier and monitor nephritis activity in the follow up. This, in turn, may guide the clinician to an earlier and more disease activity adapted treatment and thereby help improving the prognosis of SLE nephritis.
Several questions are open at present and will be addressed in near future. First of all, it would be important to identify the specificity of urinary CD4 + T cells and CXCR3 + T cells for SLE and their impact to differentiate tissue damage caused by other reasons such as hypertensive or anti-phospholipide antibodydriven nephropathy. The comparison with other biomarkers and long-term follow-up investigations in the clinical practice will provide insight whether this parameter is practicable and offer additional information not given by traditional markers.
